APLS 2018 Proxy Statement

equal to $10.03 per share. This option grant will vest as to 25% of the shares on October 18, 2018 and with respect to the remaining shares in approximately equal monthly installments through the fourth anniversary of the grant, subject to continued service. In February 2018, our board of directors granted options to purchase 280,000, 110,000 and 25,000 shares of common stock to Dr. Francois, Dr. Deschatelets and Mr. Sullivan, respectively, at an exercise price equal to $14.95 per share. Each of these options vests with respect to 25% of the shares on February 16, 2019 and with respect to the remaining shares in approximately equal monthly installments through the fourth anniversary of the grant, subject to continued service. We do not provide perquisites or personal benefits to our named executive officers. We do, however, pay the premiums for life and medical insurance for all of our employees, including our named executive officers. Outstanding Equity Awards at 2017 Fiscal Year End The following table sets forth information regarding outstanding equity awards held by our named executive officers as of December 31, 2017, which consisted entirely of stock options. Name Number of Securities Underlying Unexercised Options Exercisable (#) Number of Securities Underlying Unexercised Options Unexercisable (#) Option Exercise Price ($/share) Option Expiration Date Cedric Francois, M.D., Ph.D. . . . . . . . . . . . . . . . — 421,940(1) 4.31 8/20/27 162,078 191,547(2) 3.76 2/7/26 515,705 — 2.67 12/4/23 468,823 — 2.14 5/12/20 Pascal Deschatelets, Ph.D. . . . . . . . . . . . . . . . . . — 187,529(1) 4.31 8/20/27 104,268 123,226(2) 3.76 2/7/26 398,499 — 2.67 12/4/23 234,411 — 2.14 5/12/20 Timothy Sullivan . . . . . . . . . . . . . . . . . . . . . . . . . — 398,499(3) 10.03 10/17/27 (1) Granted on August 21, 2017. This option grant will vest as to 25% of the shares underlying the option on August 21, 2018. The remaining 75% of the shares underlying the option will vest in equal monthly installments thereafter through August 21, 2021, subject to continued service. All shares subject to vesting under this option grant will vest in full and become immediately exercisable upon the closing of a change in control of our company. (2) Granted on February 8, 2016. This option grant vested as to 25% of the shares underlying the option on February 8, 2017. The remaining 75% of the shares underlying the option will vest in equal monthly installments thereafter through February 8, 2020, subject to continued service. All shares subject to vesting under this option grant will vest in full and become immediately exercisable upon the closing of a change in control of our company. (3) Granted on October 18, 2017. This option grant will vest as to 25% of the shares underlying the option on October 18, 2018. The remaining 75% of the shares underlying the option will vest in equal monthly installments thereafter through October 18, 2021, subject to continued service. All shares subject to vesting under this option grant will vest in full and become immediately exercisable upon the closing of a change in control of our company. - 20 -